Borah Slater Khushboo, Kim Daniel, Chand Pooja, Xu Ye, Shaikh Hanif, Undale Vaishali
School of Biosciences, Faculty of Health and Microbial Sciences, University of Surrey, Guildford GU27XH, UK.
Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Pune 411018, India.
Trop Med Infect Dis. 2023 Feb 3;8(2):100. doi: 10.3390/tropicalmed8020100.
Tuberculosis (TB) is one of the ten infectious diseases that cause the highest amount of human mortality and morbidity. This infection, which is caused by a single pathogen, , kills over a million people every year. There is an emerging problem of antimicrobial resistance in TB that needs urgent treatment and management. Tuberculosis treatment is complicated by its complex drug regimen, its lengthy duration and the serious side-effects caused by the drugs required. There are a number of critical issues around drug delivery and subsequent intracellular bacterial clearance. Drugs have a short lifespan in systemic circulation, which limits their activity. Nanomedicine in TB is an emerging research area which offers the potential of effective drug delivery using nanoparticles and a reduction in drug doses and side-effects to improve patient compliance with the treatment and enhance their recovery. Here, we provide a minireview of anti-TB treatment, research progress on nanomedicine and the prospects for future applications in developing innovative therapies.
结核病是导致人类死亡率和发病率最高的十种传染病之一。这种由单一病原体引起的感染每年导致超过一百万人死亡。结核病中出现的抗菌药物耐药性问题亟待治疗和管理。结核病治疗因复杂的药物治疗方案、较长的疗程以及所需药物引起的严重副作用而变得复杂。在药物递送和随后的细胞内细菌清除方面存在许多关键问题。药物在体循环中的寿命较短，这限制了它们的活性。结核病纳米医学是一个新兴的研究领域，它提供了使用纳米颗粒有效递送药物的潜力，并减少药物剂量和副作用，以提高患者对治疗的依从性并促进其康复。在此，我们对结核病治疗、纳米医学的研究进展以及在开发创新疗法方面的未来应用前景进行简要综述。
